Vitasora Health Limited
VHL.ASXHealth Care
e-Health SaaS company supporting respiratory health management.
Market Data
$0.012
+0.1%$28.1M
-100000.0x
$-0.007
0.00%
-0.5%
Latest Earnings
Appendix 4D and Half Year Financial Report
27 February 2026
Vitasora Health Limited (VHL) reported HY FY2026 operating revenue of $2.30M (up ~147% pcp) with total revenue including R&D incentives of $2.85M (up 84.5% pcp), driven by expanding U.S. Remote Patient Monitoring patient programs reaching 22,880. However, net losses widened 40.9% to $5.13M as the company continues its strategic investment phase, with operating cash outflows of $5.78M. The company enters H2 FY2026 with improving billing productivity, favourable reimbursement reforms effective January 2026, and a pipeline of new client contracts, though it remains pre-profitability and reliant on ongoing capital raises. Key points: Operating revenue grew approximately 147% pcp to $2.30M, with total revenue (including R&D incentives) up 84.5% to $2.85M, reflecting strong patient program expansion.; Patient programs reached 22,880 at 31 December 2025, with ~1,600 new enrolments in the December quarter from existing contracted clients.; Daily clinical billing improved ~22% in December vs September 2025 baseline, with run-rate entering January 2026 more than 50% higher than September 2025.
Recent Announcements
Updated Notice of Initial Substantial Holder
Peters Investments Pty Ltd became a substantial holder in Vitasora Health Limited on 17 July 2026, acquiring 300,000,000 ordinary shares (12.86% voting power) for $33,000,000 cash on 17 July 2026.
Notice of Initial Substantial Holder
Peters Investments Pty Ltd became a substantial holder of Vitasora Health Limited on 17 June 2026, acquiring 3,000,000 ordinary fully paid shares representing 12.82% voting power for cash consideration of $3,600,000.
Appendix 4D and Half Year Financial Report
Vitasora Health Limited (VHL) reported HY FY2026 operating revenue of $2.30M (up ~147% pcp) with total revenue including R&D incentives of $2.85M (up 84.5% pcp), driven by expanding U.S. Remote Patient Monitoring patient programs reaching 22,880. However, net losses widened 40.9% to $5.13M as the company continues its strategic investment phase, with operating cash outflows of $5.78M. The company enters H2 FY2026 with improving billing productivity, favourable reimbursement reforms effective January 2026, and a pipeline of new client contracts, though it remains pre-profitability and reliant on ongoing capital raises. Key points: Operating revenue grew approximately 147% pcp to $2.30M, with total revenue (including R&D incentives) up 84.5% to $2.85M, reflecting strong patient program expansion.; Patient programs reached 22,880 at 31 December 2025, with ~1,600 new enrolments in the December quarter from existing contracted clients.; Daily clinical billing improved ~22% in December vs September 2025 baseline, with run-rate entering January 2026 more than 50% higher than September 2025.
Get real-time alerts for VHL
Receive AI-powered earnings summaries and instant notifications when Vitasora Health Limited releases results.
Register Free